[177Lu]Lu-OncoFAP-23

N/A

Report date: 2025/11/28 15:16:41

NME

Base Information

Drug Name[177Lu]Lu-OncoFAP-23

Drug Alias Name[177Lu]Lu-OncoFAP-23

ClassificationRadiation-emitting products > Radioactive therapeutic agentSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4]

Mechanisms of ActionFibroblast activation protein alpha binders

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsAdenomatous Polyposis Coli

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesPhilogen Spa

China Registration ClassN/A

Develop Information

Active CompaniesPhilogen Spa

Inactive CompaniesN/A

Active IndicationsAdenomatous Polyposis Coli

Inactive IndicationsN/A

Other Information

ATC CodeN/A